Overview

Niraparib (PHONIRA) 100 mg tablets are most powerful when used as part of a planned combination: maintenance therapy that pairs PARP inhibition with anti-angiogenic or platinum-based strategy to deepen remission in ovarian cancer. For B2B buyers, the combination context rather than monotherapy alone defines how this agent is procured and sequenced. This guide reviews the rational combinations and what they mean for supply planning.

How It Works

Niraparib is a potent PARP inhibitor that traps PARP enzymes on damaged DNA and blocks base-excision repair. In tumor cells already burdened by homologous-recombination deficiency, this synthetic-lethal pressure is amplified. When combined with bevacizumab, the anti-VEGF agent normalizes abnormal tumor vasculature and further compromises DNA repair capacity, producing deeper and longer progression-free survival than either approach used alone. The synergy arises because the two drugs attack complementary vulnerabilities, one at the vasculature and one at the DNA-repair machinery.

Indications

Niraparib is indicated for maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer that is in complete or partial response to platinum-based chemotherapy. In HRD-positive disease, it is used in combination with bevacizumab as first-line maintenance. Procurement should anticipate steady, ongoing demand because maintenance regimens are administered continuously for extended periods rather than as short courses.

Dosage & Administration

The presentation is 100 mg film-coated tablets, 30 tablets per box. Maintenance dosing is taken orally once daily, with dose modifications guided by body weight, platelet counts and tolerability. Tablets are swallowed whole. Buyers should align order volumes with long-term maintenance schedules, since interrupted supply directly undermines the continuous-inhibition strategy that combinations rely upon.

Storage & Sourcing

Store at room temperature below 30 °C, protected from light and moisture. Niraparib should be sourced from licensed manufacturers such as Tlph, Beacon or Everest with verifiable GMP status. Because combination maintenance is a sustained therapy, forecasting demand and securing batch consistency are more important than for episodic treatments.

FAQ

Q: Why combine niraparib with bevacizumab instead of using it alone? The anti-VEGF agent weakens tumor vasculature and repair capacity while niraparib blocks DNA repair, producing complementary synthetic-lethal pressure that extends remission beyond monotherapy.

Q: Which patients fit the combination approach? Those with HRD-positive ovarian cancer in first-line maintenance, or recurrent disease responding to platinum, are the primary combination candidates per labeling.

Q: What sourcing factors matter most for maintenance therapy? Continuous dosing means forecast accuracy, batch consistency and authenticated GMP supply outweigh one-time price considerations.